{
  "doc_id": "HTA_submission_sotosorib_FR",
  "created_date": "2022",
  "country": "FR",
  "source_type": "hta_submission",
  "chunks": [
    {
      "heading": "",
      "text": "Lung cancer Sectors: film-coated film-coated tablet",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "The essential",
      "text": "cancer cancer (NSCBC) NSCBC. NSCBC.",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "What progress?",
      "text": "line. line.",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "therapeutic therapeutic strategy?",
      "text": "chemotherapy, chemotherapy, including: thing thing as: LUMYKRAS LUMYKRAS (sotorasib) LUMYKRAS LUMYKRAS (sotorasib) available available (chemotherapy, immunotherapy) specified. specified.",
      "start_page": 2,
      "end_page": 3
    },
    {
      "heading": "ASMR",
      "text": "advanced advanced non-disease disease (NSCBN) therapy. therapy.",
      "start_page": 3,
      "end_page": 3
    },
    {
      "heading": "rendered rendered (ASMR V) in the",
      "text": "UMYKRAS UMYKRAS (sotoraSM) December December 2020; hour. hour.",
      "start_page": 3,
      "end_page": 7
    },
    {
      "heading": "TAXOL",
      "text": "(paclitaxel) generic generic NAMR: curative curative and/Teva, Teva, Sandoz",
      "start_page": 7,
      "end_page": 8
    },
    {
      "heading": "TECENTRIQ",
      "text": "exception exception (atezolizumab) patients patients __MEDDERM2__+) Squamous CBNPC 03/02/III III (moderate) OPDIVO OPDIVO (__MedTERM1__) III III (moderated) vs IVMR III",
      "start_page": 8,
      "end_page": 8
    },
    {
      "heading": "KEYTRUDA",
      "text": "1%, exception exception (_pembrolizumab) patients patients __MEDDERM2__+) *pharmacotherapeutic class; GEMZAR GEMZAR (gemcitabine) and AVASTIN (__MEDSTERM Oui__) support. support.",
      "start_page": 8,
      "end_page": 9
    },
    {
      "heading": "Conclusion",
      "text": "LUMYKRAS LUMYKRAS (sotorasib) GEMZAR GEMZAR (gemcitabine) and AVASTIN (bévacizumab), 2. 2.",
      "start_page": 9,
      "end_page": 9
    },
    {
      "heading": "INTERNATIONAL",
      "text": "defined defined as: are are on-cancer cancer (MDTERM3_), Kingdom. Kingdom.",
      "start_page": 9,
      "end_page": 10
    },
    {
      "heading": "100 100 study",
      "text": "A Phase 1/D. D. / M. M.",
      "start_page": 10,
      "end_page": 10
    },
    {
      "heading": "the the study",
      "text": "30 30 (+7) LUMYKRAS LUMYKRAS (sotorasib) route route (tablets), non-compliance non-compliance - duration of response: progression progression (1. 1.1) criteria criteria - the the disease: time time : survival survival 80% sotorasib sotorasib + SOTORASIB. SOTORASIB.",
      "start_page": 10,
      "end_page": 11
    },
    {
      "heading": "Results:",
      "text": "this this “basket” cancer. cancer.25% was was 116% response response (44 patients, 34%), cases cases (3%), were were 43% patients patients (16%) 2021. 2021.",
      "start_page": 11,
      "end_page": 13
    },
    {
      "heading": "100 100 study",
      "text": "from from 01/12/from from 01/09/2020 N124 15/03/Median Median (min-max) 9.3 (1,1-12,2) 12.2 [1,1-15,6] 15.3 (1,1-18,4) Medium Medium [IC95%] 8.4 [6,9-8,4] 10.0 [6,91-11,1] 11,1",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "comparison comparison data",
      "text": "MAIC MAIC (indirect indirect comparis).",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "limitations. limitations.",
      "text": "not not possible; priori priori ; 2 2 questionnaires: and and EQ-several several limitations: - of of living; - been been achieved;",
      "start_page": 13,
      "end_page": 14
    },
    {
      "heading": "100 100 study",
      "text": "grade grade (17%) as follows: 1 grade (27%) weeks weeks (min-max: 1-77). event event (AE) at 91%. was was 61%.",
      "start_page": 14,
      "end_page": 14
    },
    {
      "heading": "Plan Plan (RMP)",
      "text": "LUMYKRAS LUMYKRAS (sotorasib) RMP (28, 28, 2021) table table below: identified identified - risks risks - information information - hepatic hepatic impairment",
      "start_page": 15,
      "end_page": 15
    },
    {
      "heading": "from from PSURs",
      "text": "The PBRER/PSUR (Evaluation Evaluation Report) risk. risk.",
      "start_page": 15,
      "end_page": 15
    },
    {
      "heading": "the the SPC",
      "text": "“Special Special warnings/hypoplasia hypoplasia (hepatic hepatic dysplasia). all all (early-reviewed early-reviewed metapsy). Summary Summary & LUMYKRAS LUMYKRAS (sotograsib) mutation mutation [_MEDTERM0_], partial partial (44-patient) months months (IC95%: 6.9-8.4), months months (CI95%), months months (9.5-NE). baseline baseline endpoints; weeks weeks (min-max: 1-77). of of 37% (IC95%: 29-47), noted noted that: - LUMYKRAS LUMYKRAS (sotokrasib) of of disease; - Metabolism Metabolism (CBNPC)-NUMKRAS NUMKRAS (sotorasib) treatment treatment strategy: lumymras lumymras (sottorasib) cancer cancer (NSCBN) Its Its efficacy/due due to: - were were available; - its its efficacy: phase phase I/II study; - reactions reactions (nephrotoxicity nephrotoxicity type) therapeutic therapeutic alternatives",
      "start_page": 15,
      "end_page": 19
    },
    {
      "heading": "Public health interest",
      "text": "Given: - disease, disease, - covered, covered, - life, life, - care care and/course. course.",
      "start_page": 19,
      "end_page": 20
    },
    {
      "heading": "Taking into account:",
      "text": "- 28 28 (sotorasib) Phase Phase I/II study; - 14 14 %cohort cohort (report not published), approximately 40 %/20 % e. e.",
      "start_page": 20,
      "end_page": 21
    },
    {
      "heading": "External expertise",
      "text": "trial trial (HCCP) study study (HCC L.162-17) trial. trial.",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "therapeutic therapeutic strategy?>",
      "text": "Row 1: Row 2: sotorasib Row 3: Row Row 4: Row 5: Row Row 6:",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "rendered rendered (ASMR V) in the socket>",
      "text": "Row 1: Pathology of RowRecording: RowRowRelationship: Row2Representation: Row_Row_Representative: Row-Representations: Row3Recurrent: Row4Related: Row6Relevant: Row5Recommendatory: Row1Recurrence: Row7Reproductive: Row8Reternative:",
      "start_page": 3,
      "end_page": 3
    },
    {
      "heading": "rendered rendered (ASMR V) in the socket>",
      "text": "Row 1: Indication Row 2: concerned",
      "start_page": 3,
      "end_page": 3
    },
    {
      "heading": "rendered rendered (ASMR V) in the socket>",
      "text": "Row 1: Row Row 2: Strategy Row 3: Therapeutic",
      "start_page": 3,
      "end_page": 3
    },
    {
      "heading": "rendered rendered (ASMR V) in the socket> (column 1)",
      "text": "Row 1: Row Row 2: Row Row 3: SMR Row 4: ASMR Row 5: ISP Row 6: Row Row 7: Population",
      "start_page": 3,
      "end_page": 3
    },
    {
      "heading": "rendered rendered (ASMR V) in the socket> (column 1)",
      "text": "Row 1: Row Row 2: strategy Row 3: therapy",
      "start_page": 3,
      "end_page": 3
    },
    {
      "heading": "rendered rendered (ASMR V) in the socket> (column 2)",
      "text": "Row 1: xame Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: that Row 19: Row 20: target",
      "start_page": 3,
      "end_page": 3
    },
    {
      "heading": "rendered rendered (ASMR V) in the socket> (column 3)",
      "text": "Row 1: enRecording Row Pathology: Row2 Row2 (Row Pathological Pathology) Row: Row Row 3: disease disease (NSCLC) Pathology Pathology Row:treatment. treatment.",
      "start_page": 3,
      "end_page": 3
    },
    {
      "heading": "rendered rendered (ASMR V) in the socket> (column 3)",
      "text": "Row 1: Row 2:",
      "start_page": 3,
      "end_page": 3
    },
    {
      "heading": "rendered rendered (ASMR V) in the socket> (column 3)",
      "text": "Row 1: Row 2: Row 3:",
      "start_page": 3,
      "end_page": 3
    },
    {
      "heading": "heading heading TAXOL>",
      "text": "Row 1: NOC (INN)Generic PathogenCPT*NoticeSMRASMR NoticeSMRASMR (Libellé)Supports Row 2: identiRow 3: que Row 4: Yes, / Row 5: NotRaw6: Mylan Mylan TevaNon-CBNPCNo:",
      "start_page": 7,
      "end_page": 7
    },
    {
      "heading": "heading heading TAXOL>",
      "text": "Row 1: NAME Row 2: (INN) Row 3: Laboratory",
      "start_page": 7,
      "end_page": 7
    },
    {
      "heading": "heading heading TAXOL>",
      "text": "Row 1: Take Row 2: in Row 3: charge",
      "start_page": 7,
      "end_page": 7
    },
    {
      "heading": "heading heading TAXOL>",
      "text": "Row 1: SMR Row 2:",
      "start_page": 7,
      "end_page": 7
    },
    {
      "heading": "heading heading TAXOL>",
      "text": "Row 1: ASMR Row 2: (Libellé)",
      "start_page": 7,
      "end_page": 7
    },
    {
      "heading": "heading heading TAXOL> (column 1)",
      "text": "Row 1: NAME (INN) LabCPT*Indication Row 2: identi Row 3: que Row 4: Yes / Row 5: No Row 6: Row Row 7: row row 6:",
      "start_page": 7,
      "end_page": 7
    },
    {
      "heading": "heading heading TAXOL> (column 2)",
      "text": "Row 1: the the av",
      "start_page": 7,
      "end_page": 7
    },
    {
      "heading": "heading heading TAXOL> (column 3)",
      "text": "Row 1: visSMR Row 2: NA Row 3: NAP Row 4: Na Row 5: na Row 6: Important Row 7: Significant",
      "start_page": 7,
      "end_page": 7
    },
    {
      "heading": "heading heading TAXOL> (column 3)",
      "text": "Row 1: Row 2:",
      "start_page": 7,
      "end_page": 7
    },
    {
      "heading": "heading heading TAXOL> (column 4)",
      "text": "Row 1: Row 2: Row 3: Row 4:",
      "start_page": 7,
      "end_page": 7
    },
    {
      "heading": "heading heading TAXOL> (column 6)",
      "text": "Row 1: Row 2: AS Row 3: (Lib Row 4:",
      "start_page": 7,
      "end_page": 7
    },
    {
      "heading": "heading heading TAXOL> (column 7)",
      "text": "Row 1: Row 2: SMR Row 3: bellé) Row 4:",
      "start_page": 7,
      "end_page": 7
    },
    {
      "heading": "heading heading TAXOL> (column 10)",
      "text": "Row 1: Supports Row 2: Yes Row 3: No Row 4: no Row 5: NO Row 6: yes Row 7: yes",
      "start_page": 7,
      "end_page": 7
    },
    {
      "heading": "heading heading KEYTRUDA>",
      "text": "Row 1: Lilly and generics: histologyRow histologyRow 2: TECENTRIQ (_MEDTERM0_) patients1st patients1st chemotherapy20/05/2018 (registration)Important (except patients __MEDMERM3_)",
      "start_page": 8,
      "end_page": 8
    },
    {
      "heading": "heading heading KEYTRUDA> (column 1)",
      "text": "Row 1: Lilly and generics: Row Row 2: TECENTRIQ (__MEDTERM0_) CBNPC CBNPC 11232",
      "start_page": 8,
      "end_page": 8
    },
    {
      "heading": "heading heading KEYTRUDA> (column 3)",
      "text": "Row 1: Row 2: Yes Row 3: Yes Row 4: Yes",
      "start_page": 8,
      "end_page": 8
    },
    {
      "heading": "heading heading INTERNATIONAL>",
      "text": "Row 1: Row Row 2: Yes/No / PendingPopulation(s) Row 3: Row Row 4: GermanyYes_Pending Row 5: BelgiumNo (the the Pending)Row Row 6: SpainPleading N.A",
      "start_page": 9,
      "end_page": 9
    },
    {
      "heading": "the the study>",
      "text": "Row1: Open-label Open-label StudyRow2: Tolerance, Tolerance, Row2: 510 510 Row3: G12D G12D Row4: of of Therap5: alternative. alternative.",
      "start_page": 10,
      "end_page": 10
    },
    {
      "heading": "the the study>",
      "text": "Row 1: Row Row 2: The Study",
      "start_page": 10,
      "end_page": 10
    },
    {
      "heading": "the the study>",
      "text": "Row 1: Row Row 2: Inclusion",
      "start_page": 10,
      "end_page": 10
    },
    {
      "heading": "the the study>",
      "text": "Row 1: Row Row 2: Non-Inclusion",
      "start_page": 10,
      "end_page": 10
    },
    {
      "heading": "heading heading Results:>",
      "text": "Row 1: than than 23%, was 80%. sotorasib sotorasib + 1. 1.",
      "start_page": 11,
      "end_page": 11
    },
    {
      "heading": "heading heading Results:>",
      "text": "Row 1: Row Row 2: main",
      "start_page": 11,
      "end_page": 11
    },
    {
      "heading": "heading heading Results:>",
      "text": "Row 1: Row Row 2: Judgment Row 3: Secondary Row 4: Row 5: Row 6: Row 7:",
      "start_page": 11,
      "end_page": 11
    },
    {
      "heading": "heading heading Results:>",
      "text": "Row 1: Row Row 2: results",
      "start_page": 11,
      "end_page": 11
    },
    {
      "heading": "heading heading Results:> (from previous page)",
      "text": "Row 1: Patients Row 2: CBNPC Row 3: (N126) Row 4: Row Row 5: Median (min-max)64 (31-30%) Row 16: Row Row 10:Sex, n (%) Row 8: ECOG, n% Row 9: 0 138 (30%) 87 (70%)",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "100 100 study",
      "text": "Row 1: ofRow ofRow 1/12/Row Row 2: data ofmonth 3: 01/09/202015/03/10/08D Row 4: [N123N124] Row 5: Row Row 6: Median (min-max)9,3 (1,1-12,2)8 8 Row: [N,1238,818]",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "100 100 study",
      "text": "Row 1: Row Row 2: from 01/12/2020 Row 3: N124",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "Plan Plan (RMP)>",
      "text": "Row 1: Row Row 2: Diarrhoea64 (51%)7 (6%) Row 3: Nausea39(31%)1 (1%) Row 4: Fatigue32 (25%)3 (2%) Row 5: Arthralgie27 (21%)3 (11%)Row 6: AST27 AST27 (31%)27%9",
      "start_page": 14,
      "end_page": 14
    },
    {
      "heading": "Plan Plan (RMP)>",
      "text": "Row 1: Row Row 2: grades",
      "start_page": 14,
      "end_page": 14
    },
    {
      "heading": "Plan Plan (RMP)>",
      "text": "Row 1: Row Row 2: 3",
      "start_page": 14,
      "end_page": 14
    },
    {
      "heading": "RCP RCP data> (from previous page)",
      "text": "Row 1: Row Row 2: studydata Row 3: 2022 2022 - Row Row 4: IFCT-12i",
      "start_page": 18,
      "end_page": 18
    },
    {
      "heading": "External External expertise>",
      "text": "Row 1: validation validation date*: 07/02/2022 Review date: 20/04/2022 Adoption date: 11/05/hearing hearing date: 15/06/2022 Row 2: Stakeholders (including patients’ and users’ associations)Yes Row 3: Row Row 4: 240 240 film- coated tablets:",
      "start_page": 21,
      "end_page": 21
    }
  ]
}